Lumateperone Tosylate Patent Expiration
Lumateperone Tosylate is Used for treating schizophrenia, bipolar depression, and bipolar disorder by modulating serotonin and dopamine receptor activity. It was first introduced by Intra-Cellular Therapies Inc
Lumateperone Tosylate Patents
Given below is the list of patents protecting Lumateperone Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Caplyta | US11753419 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | Dec 10, 2040 | Intra-cellular |
| Caplyta | US12122792 | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders | Dec 10, 2040 | Intra-cellular |
| Caplyta | US12090155 | Methods | Jul 07, 2040 | Intra-cellular |
| Caplyta | US11980617 | Methods of treating acute depression and/or acute anxiety | Oct 27, 2039 | Intra-cellular |
| Caplyta | US10695345 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | Aug 30, 2039 | Intra-cellular |
| Caplyta | US11052084 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | Aug 30, 2039 | Intra-cellular |
| Caplyta | US11690842 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | Aug 30, 2039 | Intra-cellular |
| Caplyta | US11806348 | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate | Aug 30, 2039 | Intra-cellular |
| Caplyta | US12070459 | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate | Aug 30, 2039 | Intra-cellular |
| Caplyta | US12128043 | Pharmaceutical capsules comprising lumateperone mono-tosylate | Aug 30, 2039 | Intra-cellular |
| Caplyta | US10960009 | Methods of treating schizophrenia and depression | Dec 03, 2034 | Intra-cellular |
| Caplyta | US11026951 | Methods of treating bipolar disorder | Dec 03, 2034 | Intra-cellular |
| Caplyta | US9956227 | Method for the treatment of residual symptoms of schizophrenia | Dec 03, 2034 | Intra-cellular |
| Caplyta | USRE48839 | Methods and compositions for sleep disorders and other disorders | Aug 19, 2033 | Intra-cellular |
| Caplyta | US8598119 | Methods and compositions for sleep disorders and other disorders | Dec 28, 2029 | Intra-cellular |
| Caplyta | US8648077 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | Dec 01, 2029 | Intra-cellular |
| Caplyta | US10117867 | Methods and compositions for sleep disorders and other disorders | May 27, 2029 | Intra-cellular |
| Caplyta | US9168258 | Methods and compositions for sleep disorders and other disorders | May 27, 2029 | Intra-cellular |
| Caplyta | US9616061 | Methods and compositions for sleep disorders and other disorders | May 27, 2029 | Intra-cellular |
| Caplyta | US9199995 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | Mar 12, 2029 | Intra-cellular |
| Caplyta | US9586960 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | Mar 12, 2029 | Intra-cellular |
| Caplyta | USRE48825 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | Mar 12, 2029 | Intra-cellular |
| Caplyta | USRE48825 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | Feb 12, 2029 | Intra-cellular |
| Caplyta | US10464938 | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof | Mar 12, 2028 | Intra-cellular |
| Caplyta | US7183282 | Substituted heterocycle fused γ-carbolines |
Jun 15, 2020
(Expired) | Intra-cellular |
| Caplyta | USRE39680 | Substituted heterocycle fused gamma-carbolines |
Jun 15, 2020
(Expired) | Intra-cellular |
Lumateperone Tosylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List